Literature DB >> 16451807

Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo.

L K Harper1, S R Beckett, C A Marsden, A C McCreary, S P H Alexander.   

Abstract

In this study, we have used the selective A 2A adenosine receptor antagonist KW6002 to investigate the function of A 2A receptors in the Lister hooded rat nucleus accumbens in vitro and in vivo. Radioligand binding studies confirmed a greater than 50-fold selectivity of KW6002 for A 2A receptors compared to A1 receptors. Release of [3H]-dopamine from nucleus accumbens slices in vitro was almost doubled in the presence of 300 nM KW6002, while GABA release was inhibited by approximately one third. In vivo, intraperitoneal administration of KW6002 (4 mg kg(-1)) increased dopamine overflow almost 4-fold in the nucleus accumbens. In behavioural testing, KW6002 elicited place preference and increased locomotor activity at 1, 2 and 4 mg kg(-1). Taken together, these results suggest a role for tonic activation of A 2A adenosine receptors in reward-related phenomena.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451807     DOI: 10.1016/j.pbb.2005.12.014

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Adenosine A2A receptors in the nucleus accumbens bi-directionally alter cocaine seeking in rats.

Authors:  Casey E O'Neill; McKenzie L LeTendre; Ryan K Bachtell
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  On the role of adenosine (A)₂A receptors in cocaine-induced reward: a pharmacological and neurochemical analysis in rats.

Authors:  Karolina Wydra; Krystyna Gołembiowska; Agata Suder; Katarzyna Kamińska; Kjell Fuxe; Małgorzata Filip
Journal:  Psychopharmacology (Berl)       Date:  2014-07-16       Impact factor: 4.530

3.  Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.

Authors:  Sd Lane; Ce Green; Jl Steinberg; L Ma; Jm Schmitz; N Rathnayaka; Sd Bandak; S Ferre; Fg Moeller
Journal:  J Addict Res Ther       Date:  2012-03-28

4.  Istradefylline: first global approval.

Authors:  Rosselle Dungo; Emma D Deeks
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats.

Authors:  Laura Font; Susana Mingote; Andrew M Farrar; Mariana Pereira; Lila Worden; Colin Stopper; Russell G Port; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-05-20       Impact factor: 4.530

6.  Activation of adenosine A₂A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation.

Authors:  Nicola Simola; Giulia Costa; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2015-11-13       Impact factor: 4.530

7.  Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice.

Authors:  Chih W Hsu; C Y Chen; Chin-Shine Wang; Ted H Chiu
Journal:  Psychopharmacology (Berl)       Date:  2009-01-24       Impact factor: 4.530

8.  Microwave-assisted ring closure reactions: synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinediones.

Authors:  Joachim C Burbiel; Jörg Hockemeyer; Christa E Müller
Journal:  Beilstein J Org Chem       Date:  2006-10-27       Impact factor: 2.883

9.  Upregulation of Src Family Tyrosine Kinases in the Rat Striatum by Adenosine A2A Receptors.

Authors:  Li-Min Mao; Shannon Demehri; John Q Wang
Journal:  J Mol Neurosci       Date:  2022-01-18       Impact factor: 2.866

Review 10.  The Role of Adenosine Receptors in Psychostimulant Addiction.

Authors:  Inmaculada Ballesteros-Yáñez; Carlos A Castillo; Stefania Merighi; Stefania Gessi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.